Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.
Status:
Unknown status
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine how well this combination of chemotherapy drugs
works with bevacizumab in eliminating primary tumor in the breast prior to
surgery(pathological complete response or pCR in the breast). Bevacizumab is a drug that
works by blocking new blood vessel formation by the tumor cells. Giving chemotherapy and
bevacizumab before surgery may allow for lesser amount of breast tissue to be removed. To be
able to predict in the future which patients are more likely to get pCR to this drug
combination, specialized tests on tumor tissue will be performed.
Phase:
Phase 2
Details
Lead Sponsor:
University of Tennessee Cancer Institute
Collaborators:
Celgene Corporation Genentech, Inc. National Comprehensive Cancer Network